R. Jinks

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

M. van Glabbeke, M. Sydes, A. McTiernan, 2012, European Journal of Cancer.

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.

M. van Glabbeke, M. Sydes, A. McTiernan, 2011, European journal of cancer.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

M. Parmar, I. Godsland, N. Clarke, 2013, The Lancet. Oncology.

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.

L. Trani, M. van Glabbeke, M. Sydes, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Sample size for multivariable prognostic models

R. C. Jinks, R. Jinks, 2012 .

Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data

Patrick Royston, Rachel C. Jinks, Mahesh KB Parmar, 2015, BMC Medical Research Methodology.

Measuring the impact of methodological research: a framework and methods to identify evidence of impact

Babak Choodari-Oskooei, Jayne F Tierney, B. Choodari-Oskooei, 2014, Trials.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

M. Parmar, I. Godsland, N. Clarke, 2013, The Lancet. Oncology.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

M. Parmar, I. Godsland, N. Clarke, 2013, The Lancet. Oncology.